FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293150332> ?p ?o ?g. }

• W4293150332 endingPage "5042" @default.
• W4293150332 startingPage "5025" @default.
• W4293150332 abstract "Three novel androgen receptor inhibitors are approved in the USA for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide, enzalutamide, and darolutamide. All three therapies have demonstrated prolonged metastasis-free survival in their respective phase III trials, with differing safety profiles. The objective of this study was to compare the mean per-patient costs of all-cause adverse events (AEs) requiring hospitalization between darolutamide versus apalutamide and enzalutamide for nmCRPC in the USA.All-cause grade ≥ 3 AEs with corresponding any-grade AEs reported among at least 10% of patients in any arm of the ARAMIS (darolutamide), SPARTAN (apalutamide), and PROSPER (enzalutamide) trials were selected for inclusion in the primary analyses. After matching-adjusted indirect comparison, AE costs were calculated by multiplying the AE rates from the trials by their respective unit costs of hospitalization taken from the US Healthcare Cost and Utilization Project (HCUP) database. Sensitivity analyses which further included any-grade AEs reported among at least 5% of patients were also performed.After reweighting and adjusting for the trials' placebo arms, the mean per-patient AE costs were $1021 and $387 lower for darolutamide than for apalutamide and enzalutamide, respectively, over the trials' duration (SPARTAN and PROSPER, 43 months; ARAMIS, 48 months). For darolutamide vs. apalutamide, the largest drivers of the per-patient cost differences were fracture (adjusted difference $416), hypertension ($143), and rash ($219); for darolutamide vs. enzalutamide, they were fatigue not including asthenia ($290) and hypertension including increased blood pressure (i.e., any AE of hypertension or with elevated blood pressure not yet classified as hypertension) ($60). The results of the sensitivity analyses were consistent with the primary results.Patients with nmCRPC treated with darolutamide in ARAMIS incurred lower AE-related costs (USD), as determined using HCUP costing data, compared with patients treated with either apalutamide (in SPARTAN) or enzalutamide (in PROSPER)." @default.
• W4293150332 created "2022-08-27" @default.
• W4293150332 creator A5009613880 @default.
• W4293150332 creator A5011527580 @default.
• W4293150332 creator A5021183522 @default.
• W4293150332 creator A5035620882 @default.
• W4293150332 creator A5047895999 @default.
• W4293150332 creator A5048586699 @default.
• W4293150332 creator A5051432506 @default.
• W4293150332 creator A5068725802 @default.
• W4293150332 creator A5088518998 @default.
• W4293150332 date "2022-08-26" @default.
• W4293150332 modified "2023-10-06" @default.
• W4293150332 title "The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison" @default.
• W4293150332 cites W2092901728 @default.
• W4293150332 cites W2150402649 @default.
• W4293150332 cites W2292137525 @default.
• W4293150332 cites W2792086148 @default.
• W4293150332 cites W2810806599 @default.
• W4293150332 cites W2885695264 @default.
• W4293150332 cites W2885698302 @default.
• W4293150332 cites W2913767564 @default.
• W4293150332 cites W2970590492 @default.
• W4293150332 cites W2981214587 @default.
• W4293150332 cites W2994413817 @default.
• W4293150332 cites W2995389688 @default.
• W4293150332 cites W2999886889 @default.
• W4293150332 cites W3033718997 @default.
• W4293150332 cites W3036384609 @default.
• W4293150332 cites W3093310001 @default.
• W4293150332 cites W3096552042 @default.
• W4293150332 cites W3126274126 @default.
• W4293150332 cites W3127966588 @default.
• W4293150332 cites W3131141213 @default.
• W4293150332 cites W3134316062 @default.
• W4293150332 cites W3145062445 @default.
• W4293150332 cites W3145952188 @default.
• W4293150332 cites W3165392750 @default.
• W4293150332 cites W3171092095 @default.
• W4293150332 cites W3172577062 @default.
• W4293150332 cites W3179702238 @default.
• W4293150332 cites W3187603335 @default.
• W4293150332 doi "https://doi.org/10.1007/s12325-022-02245-8" @default.
• W4293150332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36028656" @default.
• W4293150332 hasPublicationYear "2022" @default.
• W4293150332 type Work @default.
• W4293150332 citedByCount "3" @default.
• W4293150332 countsByYear W42931503322022 @default.
• W4293150332 countsByYear W42931503322023 @default.
• W4293150332 crossrefType "journal-article" @default.
• W4293150332 hasAuthorship W4293150332A5009613880 @default.
• W4293150332 hasAuthorship W4293150332A5011527580 @default.
• W4293150332 hasAuthorship W4293150332A5021183522 @default.
• W4293150332 hasAuthorship W4293150332A5035620882 @default.
• W4293150332 hasAuthorship W4293150332A5047895999 @default.
• W4293150332 hasAuthorship W4293150332A5048586699 @default.
• W4293150332 hasAuthorship W4293150332A5051432506 @default.
• W4293150332 hasAuthorship W4293150332A5068725802 @default.
• W4293150332 hasAuthorship W4293150332A5088518998 @default.
• W4293150332 hasBestOaLocation W42931503321 @default.
• W4293150332 hasConcept C121608353 @default.
• W4293150332 hasConcept C126322002 @default.
• W4293150332 hasConcept C142724271 @default.
• W4293150332 hasConcept C143998085 @default.
• W4293150332 hasConcept C197934379 @default.
• W4293150332 hasConcept C204787440 @default.
• W4293150332 hasConcept C27081682 @default.
• W4293150332 hasConcept C2776551883 @default.
• W4293150332 hasConcept C2777899217 @default.
• W4293150332 hasConcept C2778570526 @default.
• W4293150332 hasConcept C2780192828 @default.
• W4293150332 hasConcept C61367390 @default.
• W4293150332 hasConcept C71924100 @default.
• W4293150332 hasConceptScore W4293150332C121608353 @default.
• W4293150332 hasConceptScore W4293150332C126322002 @default.
• W4293150332 hasConceptScore W4293150332C142724271 @default.
• W4293150332 hasConceptScore W4293150332C143998085 @default.
• W4293150332 hasConceptScore W4293150332C197934379 @default.
• W4293150332 hasConceptScore W4293150332C204787440 @default.
• W4293150332 hasConceptScore W4293150332C27081682 @default.
• W4293150332 hasConceptScore W4293150332C2776551883 @default.
• W4293150332 hasConceptScore W4293150332C2777899217 @default.
• W4293150332 hasConceptScore W4293150332C2778570526 @default.
• W4293150332 hasConceptScore W4293150332C2780192828 @default.
• W4293150332 hasConceptScore W4293150332C61367390 @default.
• W4293150332 hasConceptScore W4293150332C71924100 @default.
• W4293150332 hasFunder F4320307771 @default.
• W4293150332 hasIssue "11" @default.
• W4293150332 hasLocation W42931503321 @default.
• W4293150332 hasLocation W42931503322 @default.
• W4293150332 hasLocation W42931503323 @default.
• W4293150332 hasOpenAccess W4293150332 @default.
• W4293150332 hasPrimaryLocation W42931503321 @default.
• W4293150332 hasRelatedWork W2113899328 @default.
• W4293150332 hasRelatedWork W2169404610 @default.
• W4293150332 hasRelatedWork W2309274182 @default.
• W4293150332 hasRelatedWork W2469134207 @default.
• W4293150332 hasRelatedWork W2921176969 @default.

• next